

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2804-J

Raymond G. Goodwin, Craig A. Smith,
and Richard J. Armitage

Serial No.: -- to be assigned –
(Divisional of 09/628,126)

Examiner: to be assigned

Filing Date: October 2, 2003

For: CD 30 LIGAND

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P. O. Box 1450

Alexandria VA. 22313-1450

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R §1.56 Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449. In accordance with 37 C.F.R. § 1.98(d), copies of these publications are not enclosed as they were previously submitted in an Information Disclosure Statement complying with 37 C.F.R. §1.98 (a)-(c), in parent application serial no. 09/628,126 , which is relied on for an earlier effective filing date under 35 U.S.C. 120.

Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application. As this statement is being filed within three months of the filing date of this national application, no fee is believed due.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,



Patricia Anne Perkins
Agent for Applicants
Registration No. 34,693
Tel: 206-265-4782
October 2, 2003

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2804-J	SERIAL NO. --to be assigned-- Divisional of 09/628,126		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Raymond G. Goodwin et al.,					
		FILING DATE October 2, 1993	GROUP --to be assigned--				
U.S. PATENT DOCUMENTS							
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,165,923	11/24/92	Thorpe et al.	424		
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 93/10232	5/27/93	PCT			X
		WO 91/07437	5/30/91	PCT			X
		WO 87/07144	12/3/87	PCT			
		EP 0 412050 A1	2/6/91	EP			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40," <i>Nature</i> 357: 80-82, 1992.					
		Zsebo et al., "Stem Cell Factor is Encoded at the SI Locus of the Mouse and is the Ligand for the c-kit Tyrosine Kinase Receptor," <i>Cell</i> 63: 213-224, 1990.					
		Schwarting et al., "Cluster report: CD30," <i>Leucocyte Typing IV: White Cell Differentiation Antigens</i> : p 419-422, Oxford University Press, 1989.					
		Berenbeck et al., "Detection of soluble Hodgkin-associated CD30 antigen in the sera of patients with Hodgkin's lymphoma," <i>Leucocyte Typing IV: White Cell Differentiation Antigens</i> : p 425, Oxford University Press, 1989.					
		Dallenbach et al., "Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/leukaemia (ATL): a marker for disease activity," <i>Leucocyte Typing IV: White Cell Differentiation Antigens</i> : p. 426-428, Oxford University Press, 1989.					
		Smith et al., "CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF," <i>Cell</i> 73: 1349-1360, 1993.					
		Gruss et al., "CD30 Ligand: Molecular Cloning and Pathobiological Role in CD30-Positive Malignant Lymphomas," presented at Keystone Symposium on B and T Cell Lymphomas, Copper Mountain, CO, April 17-24, 1993.					
		Loh et al., "Polymerase Chain Reaction with Single-Sided Specificity: Analysis of T Cell Receptor δ Chain," <i>Science</i> 243: 217-220, 1989.					
		Falini et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," <i>Lancet</i> 339: 1195-1196, 1992.					
				DATE CONSIDERED			
EXAMINER							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 INFORMATION DISCLOSURE CITATION <i>(Supplemental Sheet)</i>		U.S. DEPARTMENT OF COMMERCE									
		PATENT AND TRADEMARK OFFICE									
		ATTY. DOCKET NO.	SERIAL NO.								
		2804-J	-to be assigned— Divisional of 09/628,126								
<table border="1"> <tr> <td colspan="2">APPLICANT</td> </tr> <tr> <td colspan="2">Raymond G. Goodwin, et al.</td> </tr> <tr> <td>FILING DATE</td> <td>GROUP</td> </tr> <tr> <td>October 2, 2003</td> <td>to be assigned</td> </tr> </table>				APPLICANT		Raymond G. Goodwin, et al.		FILING DATE	GROUP	October 2, 2003	to be assigned
APPLICANT											
Raymond G. Goodwin, et al.											
FILING DATE	GROUP										
October 2, 2003	to be assigned										
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
da Costa et al., "Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: Results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3," <i>Ann. Onc. 3 (Suppl. 4)</i> : S53-S57, 1992.											
Engert et al., "Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease," <i>Cancer Res. 50</i> : 84-88, 1990.											
Engert et al., "Experimental therapy in Hodgkin's disease," <i>Ann. Onc. 3 (Suppl. 4)</i> : S97-S100, 1992.											
Stein et al., "Three new lymphoid activation antigens," <i>Leucocyte Typing III: White Cell Differentiation Antigens</i> , p. 574, Oxford University Press, 1987.											
Schwarting et al., "BER-H2: a new monoclonal antibody of the Ki-1 family for the detection of Hodgkin's disease in formaldehyde-fixed tissue sections," <i>Leucocyte Typing III: White Cell Differentiation Antigens</i> , pp. 574-575, Oxford University Press, 1987.											
Newcom et al., "The Role of Ki-1 Antigen in the Autocrine TGF β Growth Regulation of Reed-Sternberg Cells, Ki-1 Lymphoma Cells, and Activated Thymocytes," <i>Blood 80(10 Supp. 1)</i> : 305a, abstract no. 1211, Nov. 15, 1992.											
Wu et al., "EBV and Tumor Progression to Ki-1 Anaplastic Large Cell Lymphoma (ALCL)," <i>Blood 80(10 Supp. 1)</i> : 445a, Abstract no. 1771, Nov. 15, 1992.											
Goodwin et al., "The TNF/NGF Superfamily of Receptors and Their Ligands," <i>J. Cell. Biochem., Keystone Symposia on Molecular & Cellular Biology, Suppl. 17B</i> , abstract F020, Jan 26-Feb. 10, 1993.											
Pallesen and Hamilton-Dutoit, "Ki-1 (CD-30) Antigen is Regularly Expressed by Tumor Cells of Embryonal Carcinoma," <i>Am. J. Path. 133(3)</i> : 446-450, 1988.											
Schwarting et al., "BER-H2: A New Anti-Ki-1 (CD30) Monoclonal Antibody Directed at a Formol-Resistant Epitope," <i>Blood 74</i> : 1678-1689, 1989.											
Andreesen et al., "Human Macrophages Can Express the Hodgkin's Cell- Associated Antigen Ki-1 (CD30)," <i>Am. J. Path. 134</i> : 187-192, 1989.											
Mechtersheimer and Möller, "Expression of Ki-1 Antigen (CD30) in Mesenchymal Tumors," <i>Cancer 66(8)</i> : 1732-1737, 1990.											
Gianotti et al., "Primary Cutaneous Pleomorphic T-Cell Lymphoma Expressing CD30 Antigen," <i>Am. J. Dermatopath. 13(5)</i> : 503-508, 1991.											
Burns and Dardick, "Ki-1 Positive Non-Hodgkin's Lymphomas," <i>Am. J. Clin. Path. 93(3)</i> : 327-332, 1990.											
Piris et al., "CD30 expression in non-Hodgkin's lymphoma," <i>Histopath. 17</i> : 211-218, 1990.											
Miettinen, "CD30 Distribution," <i>Arch. Pathol. Lab. Med. 116</i> : 1197-1201, 1992.											
Piris et al., "CD30 expression in follicular lymphoma," <i>Histopath. 18</i> : 25-29, 1991.											
Maeda and Takahashi, "Characterization of skin infiltrating cells in adult T-cell leukaemia/lymphoma (ATLL): clinical, histological and immunohistochemical studies on eight cases," <i>Brit J. Derm. 121</i> : 603-612, 1989.											
EXAMINER		DATE CONSIDERED									
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>											

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2804-J	SERIAL NO. -to be assigned— Divisional of 09/628,126
INFORMATION DISCLOSURE CITATION		APPLICANT Raymond G. Goodwin, et al.			
(Supplemental Sheet)		FILING DATE October 2, 2003	GROUP To be assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Eckert et al., "Follicular Lymphoid Hyperplasia of the Skin with High Content of Ki-1 Positive Lymphocytes," <i>Am. J. Dermatopath.</i> 11(4): 345-352, 1989.					
Aruffo and Seed, "Molecular Cloning of a CD28 cDNA by a High Efficiency COS Cell Expression System," <i>Proc. Nat. Acad. Sci. USA</i> 84: 8573-8577, 1987.					
Flanagan and Leder, "The <i>kit</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," <i>Cell</i> 63: 185-194, 1990.					
Josimovic-Alasevic et al., "Ki-1 (CD30) Antigen is Released by Ki-1 Positive Tumor Cells <i>in vitro</i> and <i>in vivo</i> ," <i>Eur. J. Immunol.</i> 19: 157-162, 1989.					
Froese et al., "Biochemical Characterization and Biosynthesis of the Ki-1 Antigen in Hodgkin-Derived and Virus-Transformed Human B and T Lymphoid Cell Lines," <i>J. Immunol.</i> 139(6): 2081-2087, 1987.					
Shohat et al., "Inhibition of Cell Growth Mediated by Plasmids Encoding p53 Antisense," <i>Oncogene</i> 1: 277-283, 1987.					
Riordan and Martin, "Oligonucleotide-based Therapeutics," <i>Nature</i> 350: 442-443, 1991.					
Pfreundschuh et al., "In-vivo-Imaging von Hodgkin-Lymphomen mit monoklonalen Antikörpern," <i>Onkologie</i> 12: Supp. 1, 30-33, 1989.					
Carde et al., "Immunoscintigraphy of Hodgkin's Disease: In Vivo use of Radiolabelled Monoclonal Antibodies Derived from Hodgkin Cell Lines," <i>Eur. J. Cancer</i> 26(4): 474-479, 1990.					
Stein et al., "The Expression of the Hodgkin's Disease Associated Antigen Ki-1 in Reactive and Neoplastic Lymphoid Tissue: Evidence that Reed-Sternberg Cells and Histiocytic Malignancies Are Derived from Activated Lymphoid Cells," <i>Blood</i> 66(4): 848-853, 1985.					
Andreesen, et al., "A Hodgkin Cell-Specific Antigen is Expressed on a Subset of Auto-and Alloactivated T (Helper) Lymphoblasts," <i>Blood</i> 63(6): 1299-1302, 1984.					
Klein, "Epstein-Barr Virus-Carrying Cells in Hodgkin's Disease," <i>Blood</i> 80(2): 299-301, 1992.					
Poiesz, et al., "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma," <i>Proc. Natl. Acad. Sci. USA</i> 77(12): 7415-7419, 1980.					
Schwab et al., "Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells," <i>Nature</i> 299: 65-67, 1982.					
Stein et al., "Identification of Hodgkin and Sternberg-Reed Cells as a Unique Cell Type Derived from a Newly Detected Small-Cell Population," <i>Intl. J. Cancer</i> 30: 445-459, 1982.					
Durkop et al., "Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family that is Characteristic for Hodgkin's Disease," <i>Cell</i> 68: 421-427, 1992.					
Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy," <i>Nature</i> 337: 525-531, 1989.					
EXAMINER		DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					